



**SUPPLEMENTAL / BID BULLETIN**  
**UNIVERSITY OF THE PHILIPPINES MANILA**  
*The Health Sciences Center*  
**Bids and Awards Committee 1**  
Taft Avenue, Manila  
Trunk Line No. 8554-8400 Local 3014/3015



**BID BULLETIN NO. 2024-022**

**for the Supply and Delivery of Various Drugs and Medicines  
for Charity In-Patient and Resale – Oral Solids / Tablets  
for CY 2024 (Framework Agreement)  
8 February 2024**

Pursuant to Section 22.5.1 of the 2016 Revised Implementing Rules and Regulations of Republic Act No. 9184, the Bids and Awards Committee 1 is issuing this bid bulletin to modify or amend the following items in the Bid Documents in response to / to address the request / clarification of the prospective bidder/s who attended the pre-bid conference held on 19 January 2024:

1. *The following should be modified the Invitation to Bid (Section I) as:*

No.	From	To
<b>8</b>	Bids must be duly received by the UP-PGH BAC 1 Secretariat through manual submission at the office address indicated below, on or before 9:00AM, 02 February 2024. Late bids shall not be accepted.	Bids must be duly received by the UP-PGH BAC 1 Secretariat through manual submission at the office address indicated below, on or before <b><u>9:00AM, 16 February 2024</u></b> . Late bids shall not be accepted.
<b>10</b>	Bid opening shall be on 9:30 AM, 02 February 2024, at the given address below. Bids will be opened in the presence of the bidders' representatives who choose to attend the activity.	Bid opening shall be on <b><u>9:30 AM, 16 February 2024</u></b> at the given address below. Bids will be opened in the presence of the bidders' representatives who choose to attend the activity.

2. *The following should be modified the Special Conditions of Contract (Section V) as:*

GCC Clause	From	To
<b>1</b>	<p>Delivery and Documents –</p> <p>For purposes of the Contract, “EXW,” “FOB,” “FCA,” “CIF,” “CIP,” “DDP” and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, Paris. The Delivery terms of this Contract shall be as follows:</p>	<p>Delivery and Documents –</p> <p>For purposes of the Contract, “EXW,” “FOB,” “FCA,” “CIF,” “CIP,” “DDP” and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, Paris. The Delivery terms of this Contract shall be as follows:</p>

<b>GCC Clause</b>	<b>From</b>	<b>To</b>
	<p>[For Goods supplied from abroad, state:] “The delivery terms applicable to the Contract are DDP delivered [indicate place of destination]. In accordance with INCOTERMS.”</p> <p>“The delivery terms applicable to this Contract are delivered to the University of the Philippines Manila – Philippine General Hospital. Risk and title will pass from the Supplier to the Procuring Entity upon receipt and final acceptance of the Goods at their final destination.”</p> <p>Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in Section VI (Schedule of Requirements).</p> <p>For purposes of this Clause the Procuring Entity’s Representative at the Project Site is Maria Bernadette P. Idjao, MMPA, Chief Administrative Officer – Property and Supply Division and Emelita O. Lavilla, RND, MHA, Chief, Dietary Department.</p>	<p>[For Goods supplied from abroad, state:] “The delivery terms applicable to the Contract are DDP delivered [indicate place of destination]. In accordance with INCOTERMS.”</p> <p>“The delivery terms applicable to this Contract are delivered to the University of the Philippines Manila – Philippine General Hospital. Risk and title will pass from the Supplier to the Procuring Entity upon receipt and final acceptance of the Goods at their final destination.”</p> <p>Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in Section VI (Schedule of Requirements).</p> <p>For purposes of this Clause the Procuring Entity’s Representative at the Project Site is Maria Bernadette P. Idjao, MMPA, Chief Administrative Officer – Property and Supply Division <del>and Emelita O. Lavilla, RND, MHA, Chief, Dietary Department.</del></p>

### 3. Clarification:

#### GENERAL QUERY:

<b>Query</b>	<b>Remarks / Response</b>
<p>Revenue Memorandum Circular No. 7-2024 “Revision of Value-Added Tax Exemption of Transactions Specified Under Section 109 (BB) of the National Internal Revenue Code (Tax Code) of 1997, as amended”</p> <p><i>Is there any adjustment in the ABC of items affected for the incoming bidding of PGH?</i></p>	<p>No adjustment on the Approved Budget for the Contract (ABC).</p>

#### TERMS AND CONDITIONS:

<b>Query</b>	<b>Remarks / Response</b>
<p>Memorandum of Agreement (MOA) and Certificate of Exclusive / Authorized Distributorship</p>	<p>The title / heading of the required “MOA” may vary depending on the agreement executed by the manufacturer and exclusive / authorized distributor. However, the purpose of having the authority to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distribution agreement. Compliance with the submission of the MOA and Certificate of Exclusive / Authorized Distributorship between the manufacturer and distributor is required.</p>
<p>Renewal of Certificate of Product Registration (CPR) – Official Receipt</p>	<p>As stated in the FDA Circular No. 2011-004, the FDA considers the renewal of CPR’s as valid and existing provided it is filed within the 120-day</p>

Query	Remarks / Response
With respect to the above three (3) months requirement, may we respectfully seek clarification for the legal basis thereof since the CPRs are on its face valid, unless revoked or not renewed.	period (4 months) from its date of expiry. Compliance of the company is required to submit proof of payment and filing. The hospital is still lenient in its requirements of three (3) months.
Can we submit letter coming from the principal authorizing the company as the authorized distributor?	Submission must be supported with valid Memorandum of Agreement (MOA) and Certificate of Exclusive/Authorized Distributorship between the manufacturer and distributor.
Can we submit Certificate of Exclusive Distributorship issued and approved by our principal as stated on CPR	
What is the allowed number of months of expiration for the samples to be submitted?	Submitted Certificate of Analysis (COA) must be valid for at least 120 calendar days from the date of the opening of bids or during the process of bid evaluation and award of contract.
Single Largest Completed Contract (SLCC)	<p>As stated in Section II – Instructions to Bidders Item 5.3.b, “For the procurement of Expendable Supplies: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC”</p> <p>Statement of the Single Largest Completed Contract must be supported with:</p> <ol style="list-style-type: none"> <li>1. Contract</li> <li>2. Certificate of Completion</li> <li>3. Certificate of Acceptance</li> </ol> <p>All submitted documents will be subject to verification and validation during the post-qualification.</p>
<p>The prospective bidders are requesting to exclude the required attachment as part of the Statement of All On-Going Government and Private Contracts</p> <ol style="list-style-type: none"> <li>1. Notice of Award and/or Contract</li> <li>2. Notice to Proceed</li> </ol>	<p>Request granted.</p> <p>The Statement of All On-going Government and Private Contracts (including Contracts Awarded but not yet started) for the last two (2) years shall be provided.</p> <p>However, during the post-qualification documentations may be required if needed.</p>

4. Clarification on the following line items:

Item No.	From	To
<b>2</b>	Acetylcysteine 600mg effervescent tablet <i>Offer: Acetylcysteine 600mg powder for oral solution</i>	Acetylcysteine 600mg powder for oral solution is different from the 600mg effervescent tablet formulation, rendering it non formulary.
<b>44</b>	Cefixime 200mg capsule <i>Offer: Cefixime 200mg tablet</i>	The specifications set by the PNF shall be strictly followed.
<b>49</b>	Cetirizine di-Hydrochloride 10mg tablet <i>Offer: Cetirizine Hydrochloride 10mg tablet</i>	We will strictly follow the specifications set by HTAD in the PNF.
<b>91</b>	Fenofibrate 160 mg tablet <i>Offer: Fenofibrate 160 mg capsule</i>	We will strictly follow the specifications set by HTAD in the PNF.

Item No.	From	To
113	Imatinib mesilate 100mg tablet <i>Offer: Imatinib mesilate 100mg capsule</i>	The specifications set by the PNF shall be strictly followed.
221	Tamsulosin 400mcg prolonged release film-coated tablet <i>Offer: Tamsulosin 400mcg prolonged release film-coated capsule</i>	The specifications set by the PNF shall be strictly followed.

This shall form an integral part of the Bid Documents.

For the information and guidance of all concerned.

**Dean CHARLOTTE M. CHIONG, MD, PhD**  
*Chairperson, Bids and Awards Committee 1*

Received by the Bidder:

\_\_\_\_\_  
*Signature over Printed Name*

\_\_\_\_\_  
*Name of Company*

\_\_\_\_\_  
*Date*